Objective To investigate the effect of Avastin (bevacizumab) combined with preoperative FOLFOX neoadjuvant chemotherapy on the prognosis of patients with locally advanced rectal cancer (LARC).MethodsA total of 80 cases of patients with LARC treated with total mesorectal excision (TME) in our hospital from January 2013 to January 2016 were randomly divided into the control group and the observation group, 40 cases in each group.The control group were treated with preoperative FOLFOX chemotherapy while the observation group were treated with bevacizumab injection, based on the treatment in the control group.21 days was a cycle of chemotherapy, and both groups were treated for at least 4 cycles.After 6 cycles of chemotherapy, operation was carried out, following TEM principle.The short-term and long-term prognosis, rate of R0 resection, the incidence of postoperative complications and side effects of chemotherapy were compared between the two groups.ResultsThere was no significant difference between the two groups in the good response rate of chemotherapy, the rate of R0 resection, the incidence of postoperative complications, the 1-year and 3-year survival rates and 1-year disease-free survival rate.The incidence rates of gastrointestinal reactions and bone marrow suppression in the observation group were 52.5% and 52.5%, respectively while in the control group were 25.0% and 20.0%, respectively (P<0.05), but there was no significant difference in the incidence rates of grade Ⅲ~Ⅳ gastrointestinal reaction and bone marrow suppression between the observation group and the control group (5.0% and 15.0% vs 2.5% and 5.0%).The 3-year disease-free survival rate of the observation group was higher than that of the control group (82.5% vs 60.0%) (P<0.05).ConclusionThe application of bevacizumab combined with preoperative FOLFOX chemotherapy in the treatment of LARC can improve the 3-year disease-free survival rate, without increasing postoperative adverse reactions and serious side effects of chemotherapy.

Objective To explore the association of serum bilirubin level at the time of admission with the compos?ite outcome（disability or death）in discharged patients with acute ischemic stroke. Methods In a retrospective cohortstudy from June 1st 2009 to May 31st 2012, we continuously included 3151 patients with acute ischemic stroke and col?lected demography,lifestyle,clinical manifestations and laboratory test data. Functional outcome was measured with themodified Rankin scale (mRS) when subjects were discharged. Disability was defined as mRS≥3 and composite outcomewas defined as mRS≥3 or death. Serum bilirubin was divided into four groups according to the quartile. Multiple Coxregression analysis was used to assess the independent relation between serum bilirubin and disability death and the com?posite outcome. Results There were 407 disabled patients，the disability rate was 12.9%；and 104 patients were dead，the fatality rate was 3.3%.After adjusting for multiple factors, we found the risks of composite outcome with total bilirubin in the four quartile were higher than that in the first quartile, aHR and 95%CI were 1.335(1.047～1.702) respectively；The risks of composite outcome with indirect bilirubin in the four quartile were higher than that in the first quartile, aHR and 95%CI were 1.355(1.062～1.728) respectively; The risks of composite outcome with bilirubin direct in the third and the forth quartile were higher than that in the first quartile, aHR and 95% CI were11.403(1.089～1.807)and 1.431 (1.118～1.833) respectively.With the increase of total bilirubin，indirect bilirubin and direct bilirubin level，the compos?ite outcome of discharged patient was on the increase. Conclusions The study indicated that higher serum bilirubincould increase the risk of composite outcome in ischemic stroke patients, there was dose-response relationship ,and bili?rubin was a independent risk factor.

OBJECTIVETo observe the effect of ginsenoside Rg1 on behavior and hippocampal amino acids in depressive-like rats.

METHODSD rats were randomly divided into 5 groups: control, model, fluxetine, low dose ginsenoside Rg1 and high dose of ginsenoside Rg1. The chronic unpredictable mild stress (CUMS) was performed to induce depressive-like animal model. Fluxetine group was orally given fluxetine in dose of 10 mg x kg(-1) for 21 days, low dose ginsenoside Rg1 group was orally given ginsenoside Rg1 in dose of 20 mg x kg(-1) for 21 days, high dose ginsenoside Rg1 group was orally given ginsenoside Rg1 in dose of 40 mg x kg(-1) for 21 days. The control and model group was orally given saline for 21 days. The sucrose consumption was detected before and after the CUMS procedure. The horizontal and vertical activities of rats were determined by open-field test. HPLC was adopted to detect the contents of amino acids in hippocampus.

RESULTThe sucrose consumption, horizontal and vertical activities in CUMS rats were decreased compared with those in control group. Compared with control group, the contents of glutamate (Glu) and aspartate (Asp) in hippocampus of CUMS group were increased, while the gamma amino butyric acid (GABA) and taurine (Tau) were decreased. Ginsenoside Rg1 treatment significantly increased the CUMS-induced decrease in sucrose consumption, horizontal and vertical activities. Administrated with ginsenoside Rg1 also decreased Glu and Asp and increased the GABA and Tau in hippocampus in a dose dependent manner.

CONCLUSIONGinsenoside Rg1 could alleviate the behavior changes of depressive-like rats, which might be related to regulate the levels of amino acids in hippocampus during CUMS and prevent the neuro-toxicity of excitatory amino acids.

Amino Acids ; metabolism ; Animals ; Behavior, Animal ; drug effects ; Depression ; drug therapy ; metabolism ; psychology ; Disease Models, Animal ; Ginsenosides ; administration & dosage ; Hippocampus ; drug effects ; metabolism ; Humans ; Male ; Rats ; Rats, Sprague-Dawley